UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported):

July 29, 2025

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)


Delaware	1-8351	31-0791746
(State or other ‎jurisdiction of ‎incorporation)	(Commission File Number)	(I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:

(513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which

registered

Capital stock $1 par value

CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On July 29, 2025, Chemed Corporation issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the release is furnished herewith as Exhibit 99.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors: Appointment of Certain Officers, Compensatory Arrangements of Certain Officers.

(b) Nicholas M. Westfall, Executive Vice President of Chemed Corporation (the “Company”) and Chairman and Chief Executive Officer of Vitas, advised that he is resigning as Chairman and Chief Executive Officer of Vitas effective as of July 29, 2025, to pursue other interests. He will continue as Executive Vice President of Chemed and will assist with the transition of his duties until December 1, 2025. A copy of the press release announcing the events described above is attached hereto as Exhibit 99.

Item 9.01 Financial Statements and Exhibits


d)	Exhibit

	(99) Registrant’s press release dated June 30, 2025
	104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	CHEMED CORPORATION

Dated: July 29, 2025	By:	/s/ Michael D. Witzeman
		Michael D. Witzeman
		Executive Vice President and Chief Financial Officer

Page 3 of 3

CHEMED CORP 8-K